If a patient who is NPO and normally takes apixaban (Eliquis) needs anticoagulation, should I start a therapeutic unfractionated heparin infusion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Should You Start a Heparin Drip for an NPO Patient on Eliquis?

No, you should not routinely start a therapeutic heparin infusion when a patient on apixaban (Eliquis) is made NPO. The FDA label for Eliquis explicitly states that "bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required" 1.

Key Decision Points

For Planned Procedures

The approach depends entirely on the bleeding risk of the anticipated procedure and the indication for anticoagulation:

  • Low bleeding risk procedures: Stop Eliquis at least 24 hours before the procedure. No bridging with heparin is needed 1.

  • Moderate to high bleeding risk procedures: Stop Eliquis at least 48 hours before the procedure. Bridging is still not generally required 1.

The 2017 French guidelines on perioperative DOAC management reinforce this, stating that "bridging by UFH or LMWH is not recommended" when interrupting DOACs for procedures 2.

Critical Context: Atrial Fibrillation vs. VTE

If the patient has atrial fibrillation (the most common indication for Eliquis), the 2014 AHA/ACC/HRS guidelines state that bridging decisions "should balance the risks of stroke and bleeding" 3. However, for patients without mechanical heart valves, "it is reasonable to interrupt anticoagulation for up to 1 week without substituting heparin for surgical or diagnostic procedures that carry a risk of bleeding" 4.

If the patient has active VTE (DVT/PE), the situation differs. The 2022 cancer VTE guidelines note that unfractionated heparin "can be also used for the initial treatment of established VTE for patients with cancer when LMWH or direct oral anticoagulants are contraindicated, or not available" 5. This suggests heparin is a backup option, not a routine bridge.

Pharmacokinetic Considerations

Apixaban has a half-life of approximately 12 hours 6. The FDA label notes that "the pharmacodynamic effect of ELIQUIS can be expected to persist for at least 24 hours after the last dose, i.e., for about two drug half-lives" 1. This means:

  • After 24 hours: minimal anticoagulant effect remains
  • After 48 hours: essentially no clinically significant effect

Starting a heparin drip during this washout period adds bleeding risk without clear benefit, as the patient will have overlapping anticoagulation.

When Heparin Might Be Considered

The only scenarios where bridging with heparin may be reasonable:

  1. Mechanical heart valves: These patients require continuous anticoagulation. The 2014 AF guidelines recommend "bridging therapy with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH)" for patients with mechanical valves undergoing procedures 3.

  2. Very high thrombotic risk: Patients with recent VTE (within 1 month), recurrent VTE despite anticoagulation, or severe thrombophilia might warrant bridging, though this should be individualized 7.

  3. Prolonged NPO status without procedure: If a patient will be NPO for an extended period (>48-72 hours) without a planned procedure and has a high thrombotic risk, consider alternative anticoagulation.

Common Pitfalls to Avoid

Do not reflexively bridge all anticoagulated patients made NPO. The evidence from the PREFER in VTE registry shows that 28.8% of DOAC patients inappropriately received heparin overlap, and only 29.7% of rivaroxaban patients received the correct initial dosing 8. This represents widespread deviation from guidelines.

Heparin resistance can occur when DOACs and heparin are used together, particularly if reversal agents like prothrombin complex concentrate have been administered 9. This creates monitoring challenges and potential thrombotic risk.

The risk of heparin-induced thrombocytopenia (HIT) is as high as 5% with unfractionated heparin in certain populations 7. Unnecessary heparin exposure increases this risk without clear benefit.

Practical Algorithm

  1. Determine the indication for Eliquis: AF, VTE treatment, or VTE prophylaxis post-orthopedic surgery
  2. Assess thrombotic risk: Mechanical valve? Recent VTE? High CHADS2-VASc score?
  3. Determine bleeding risk of anticipated procedure: Low, moderate, or high?
  4. Calculate time since last Eliquis dose: Use half-life of 12 hours
  5. For most patients: Hold Eliquis 24-48 hours before procedure, no heparin bridge
  6. For mechanical valves or extreme thrombotic risk only: Consider LMWH over UFH (easier to use, lower HIT risk) 5

Resume Eliquis at least 6 hours after the procedure once adequate hemostasis is established 1. If bleeding risk remains high, delay resumption and use prophylactic-dose LMWH until safe to restart 2.

References

6
Guideline

venous thromboembolic disease.

Journal of the National Comprehensive Cancer Network : JNCCN, 2013

Related Questions

Can a patient be switched from loevnoX (low‑molecular‑weight heparin) 1 mg/kg twice daily to apixaban 10 mg twice daily, and what clinical factors need to be evaluated before making the change?
When should apixaban (Eliquis) be initiated after stopping a heparin infusion?
In a patient whose thrombotic event occurred more than three months ago, can we discontinue rivaroxaban (Xarelto) today, start a therapeutic unfractionated heparin infusion, and stop the heparin infusion on the morning of an evening surgery?
What is the recommended protocol for switching a patient from rivaroxaban to apixaban, including washout period, dosing adjustments, and need for low‑molecular‑weight heparin bridging?
When is it appropriate to transition a patient from low‑molecular‑weight heparin to a direct oral anticoagulant?
Explain in detail why inulin can be used to estimate glomerular filtration rate (GFR) and the physiological basis for its use, and why GFR is often estimated using creatinine instead.
Can minoxidil, isotretinoin (Accutane), or finasteride cause bleeding?
How should a procalcitonin level of 0.24 nanograms per milliliter be interpreted?
What are the possible causes of hypotension in a patient with multiple myeloma?
What is the appropriate dosing regimen and duration for sucrosomial iron in an adult with iron‑deficiency anemia who cannot tolerate conventional ferrous salts?
What questions should be asked when taking the history of present illness (HPI) for a patient with sore throat?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.